CH \$140.00 5541

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM491836

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SECURITY INTEREST

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
AMICUS THERAPEUTICS, INC.		09/28/2018	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	BIOPHARMA CREDIT PLC	
Street Address:	/o Beaufort House, 51 New North Road	
City:	Exeter	
State/Country:	UNITED KINGDOM	
Postal Code:	EX4 4EP	
Entity Type:	Public Limited Company: UNITED KINGDOM	

PROPERTY NUMBERS Total: 5

Property Type	Number	Word Mark
Registration Number:	5541266	GALAFOLD
Serial Number:	86839457	GALAFOLD
Serial Number:	86839465	
Serial Number:	86839473	GALAFOLD
Serial Number:	86839478	

CORRESPONDENCE DATA

Fax Number: 2128721002

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2128728078

Email: alui@akingump.com, kkoehler@akingump.com

Correspondent Name: Amanda Lui
Address Line 1: One Bryant Park

Address Line 4: New York, NEW YORK 10036

NAME OF SUBMITTER:	Kwan Koehler
SIGNATURE:	/Kwan Koehler/
DATE SIGNED:	09/28/2018

Total Attachments: 6

source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page1.tif

source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page2.tif
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page3.tif
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page4.tif
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page5.tif
source=Pharmakon-Fold -- Trademark Security Agreement (Executed)#page6.tif

TRADEMARK SECURITY AGREEMENT

THIS TRADEMARK SECURITY AGREEMENT, dated as of September 28, 2018, is made by AMICUS THERAPEUTICS, INC. ("Grantor"), in favor of BIOPHARMA CREDIT PLC (together with its successors and permitted assigns, "Lender") on behalf of itself and the other Secured Parties (as defined in the Loan Agreement referred to below).

WITNESSETH:

WHEREAS, pursuant to the Loan Agreement, dated as of September 19, 2018 (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Loan Agreement"), by and among AMICUS THERAPEUTICS, INC. ("Borrower"), CALLIDUS BIOPHARMA, INC. (as an additional Credit Party), SCIODERM, INC. (as an additional Credit Party), AMICUS THERAPEUTICS US, INC. (as an additional Credit Party), AMICUS BIOLOGICS, INC. (as an additional Credit Party) and Lender, Lender has agreed to make extensions of credit to Borrower upon the terms and subject to the conditions set forth therein;

WHEREAS, Grantor has agreed, pursuant to a Guaranty and Security Agreement dated as of September 28, 2018 in favor of Lender for the benefit of itself and the other Secured Parties (as such agreement may be amended, restated, supplemented or otherwise modified from time to time, the "Guaranty and Security Agreement"), to guarantee the Obligations (as defined in the Loan Agreement) of Borrower; and

WHEREAS, Grantor is party to the Guaranty and Security Agreement pursuant to which Grantor is required to execute and deliver this Trademark Security Agreement;

NOW, THEREFORE, in consideration of the mutual covenants, terms and conditions set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree, intending to be legally bound, as follows:

- Section 1. Defined Terms. Capitalized terms used herein without definition are used as defined in the Guaranty and Security Agreement.
- Section 2. Grant of Security Interest in Trademark Collateral. Grantor, as collateral security for the prompt and complete payment and performance when due (whether at stated maturity, by acceleration or otherwise) of the Secured Obligations, hereby mortgages, pledges and hypothecates to Lender, for the benefit of itself and the other Secured Parties, and grants to Lender, for the benefit of itself and the other Secured Parties, a Lien on and security interest in, all of its right, title and interest in, to and under the following Collateral of Grantor, in each case, solely to the extent constituting Collateral (and excluding any Excluded Property) (the "Trademark Collateral"):
 - 1.1.1. all of its Trademarks and all IP Licenses and IP Ancillary Rights providing for the grant by or to Grantor of any right under any Trademark,

including, without limitation, those referred to on Schedule 1 hereto, but excluding any "intent to use" Trademark applications for which a statement of use has not been filed (but only excluding such applications until such statement is filed);

- 1.1.2. all renewals and extensions of the foregoing;
- 1.1.3. all goodwill of the business connected with the use of, and symbolized by, each such Trademark; and
- 1.1.4. all income, royalties, proceeds and liabilities at any time due or payable or asserted under and with respect to any of the foregoing, including, without limitation, all rights to sue and recover at law or in equity for any past, present and future infringement, misappropriation, dilution, violation or other impairment thereof.
- Section 3. Guaranty and Security Agreement. The security interest granted pursuant to this Trademark Security Agreement is granted in conjunction with the security interest granted to Lender for the benefit of itself and the other Secured Parties, pursuant to the Guaranty and Security Agreement and Grantor hereby acknowledges and agrees that the obligations, rights and remedies of Grantor and of Lender on behalf of itself and the other Secured Parties with respect to the security interest in the Trademark] Collateral made and granted hereby are more fully set forth in the Guaranty and Security Agreement, the terms and provisions of which are incorporated by reference herein as if fully set forth herein.
- Section 4. Grantor Remains Liable. Grantor hereby agrees that, anything herein to the contrary notwithstanding, Grantor shall assume full and complete responsibility for the prosecution, defense, enforcement or any other reasonably necessary actions in connection with their [Copyrights] [Patents] [Trademarks] and IP Licenses subject to a security interest hereunder.
- Section 5. Counterparts. This [Copyright] [Patent] [Trademark] Security Agreement may be executed in any number of counterparts and by different parties in separate counterparts, each of which when so executed shall be deemed to be an original and all of which taken together shall constitute one and the same agreement. Signature pages may be detached from multiple separate counterparts and attached to a single counterpart.
- Section 6. Governing Law. This [Copyright] [Patent] [Trademark] Security Agreement and the rights and obligations of the parties hereto shall be governed by, and construed and interpreted in accordance with, the law of the State of New York without regard to any principle of conflicts of law that could require the application of the law of any other jurisdiction.

[Signature Page Follows]

IN WITNESS WHEREOF, Grantor has caused this Trademark Security Agreement to be executed and delivered by its duly authorized officer as of the date first set forth above.

Very truly yours,

Amicus Therapeutics, Inc., as Grantor

By: Bradley L. Campbell

Title: President

Signature Page to the Trademark Security Agreement

ACCEPTED AND AGREED as of the date first above written:

BIOPHARMA CREDIT PLC, as Lender

By: Pharmakon Advisors, LP, its Investment Manager

By: Pharmakon Management I, LLC, its General Partner

Namé. Pedro Gonzalez de Cosio

(ive: Managing Member

Signature Page to the Trademark Security Agreement

SCHEDULE I TO TRADEMARK SECURITY AGREEMENT

<u>Trademarks, Trademark Applications</u>
(including any service marks, collective marks and certification marks) and Trademark Licenses

All Trademarks listed below are owned by Amicus Therapeutics, Inc.

GAL-2CE-US	GAL-3CE-US	GAL-2BE-US	GAL-3BE-US	GAL-4BE-US	Amicus No.
31147.46	31147.45	31147,44	31147.43	3114732	LSNo
United States	Country				
		(A)) Galafold		image Title
Galafold Design Logo (Color Claim)	GALAFOLD & Design (Color Caim)	Galafold Design Logo (No Color Claim - Black & White)	GALAFOLD & Design (No Color Claim - Black & White)	GALAFOLD	Trademark
Allowed	Allowed	Allowed	Allowed	Registered	Status
86/839,478	86/839,473	86/839,465	86/839,457	86/465,401	Application Na.
12/4/2015	12/4/2015	12/4/2015	12/4/2015	11/26/2014	Application Date
				5,541,266	Registration No
				8/14/2018	Registration Date
Class 5: Pharmaceutical preparations for the treatment of Fabry disease.	Class 5: Pharmaceutical preparations for the treatment of Fabry disease.	Class 5: Pharmaceutical preparations for the treatment of Fabry disease.	Class 5: Pharmaceutical preparations for the treatment of Fabry disease.	Class 5: Pharmacoultical preparations for the treatment of Fabry disease	Class/Goords

TRADEMARK **REEL: 006472 FRAME: 0894**

RECORDED: 09/28/2018